Objectives: The aim of the research is to examine the frequency and types of anemia in patients with type 2 diabetes depending on gender, age, and therapy for the treatment of diabetes mellitus. Material and methods: The research is a cross-sectional study with historical data. The research used data collected during regular check-ups for patients with type 2 diabetes in primary health care offices in Osijek Health Center from February to June 2022. The collected data were demographic data, data on the duration of diabetes and the used therapy, data on the presence of diabetic nephropathy, fasting glucose values, values of glycosylated hemoglobin, iron, unsaturated and total iron binding capacity, hemoglobin, average erythrocyte volume, average hemoglobin in erythrocyte and average concentration of hemoglobin in erythrocyte. Results: Anemia was recorded in 19% of the subjects and was usually normocytic normochromic, characterized as mild or moderate. Etiologically, the most prevalent were anemia of chronic disease and mixed anemia. The average age of patients with anemia was 12 years higher than those without anemia. Normocytic normochromic and hypochromic anemia occurred statistically significantly more often in elderly patients, as did mixed anemia. No difference was observed in the frequency of anemia regarding the treatment of diabetes with monotherapy or combined therapy. A significantly higher frequency of anemia was observed in patients who used sulfonylurea derivatives. The first 5 years of metformin treatment were significantly associated with the onset of anemia of chronic disease, and treatment lasting longer than 10 years with the onset of mixed anemia. Conclusion: Regular screening is essential as a part of routine controls because patients with type 2 diabetes have a high incidence of anemia. This is especially significant for elderly individuals with renal insufficiency and poor disease control, as well as for patients receiving sulfonylurea derivative treatment.
Background and Objectives: Chronic kidney disease (CKD) is an increasingly significant global public health issue, with cardiovascular disease being the leading cause of mortality. Endothelial dysfunction plays a critical role, but diagnostic tools have certain limitations. Endocan, a soluble proteoglycan, emerged as a promising endothelial dysfunction marker and potential major adverse cardiovascular event (MACE) predictor in haemodialysis (HD) patients. Materials and Methods: In this single-centre, observational, prospective study, non-diabetic HD patients without prior MACEs were monitored. A total of 75 participants met the inclusion criteria. We measured serum endocan, standard biochemical and anthropometric parameters, and parameters of peripheral and central haemodynamics before and after HD in all participants. Results: Patients with higher endocan were older, had elevated CRP and reduced albumin concentrations, and often had a tunnelled central venous catheter (TCVC) for vascular access. Higher serum endocan levels were independently associated with an increased risk of MACEs (aHR = 4.09, 95%-CI: 1.72–9.74), MACE-related mortality (aHR = 2.64, 95%-CI: 1.23–5.66), and all-cause mortality (aHR = 1.86, 95%-CI: 1.07–3.23), both before and after adjusting for predefined confounders, with the highest endocan tercile exhibiting the shortest event-free survival. Conclusions: Endocan is a valuable marker of inflammation and endothelial dysfunction in non-diabetic HD patients. Its elevated concentration indicates an increased cardiovascular risk and more frequent MACEs. Future multicentre studies with repeated endocan assessments should validate its prognostic and diagnostic utility, particularly in long-term patient follow-up.
Aim To determine parameters of glycaemic control, renal function and anthropometric measurements in patients with type 2 diabetes in family medicine offices and to examine whether there is a difference in these parameters between genders. Methods This cross-sectional study included 136 patients of both genders diagnosed with type 2 diabetes, with an average age of 69.33±10.87. General and demographic data were collected, anthropometric measurements were taken, as well as data on fasting plasma glucose, HbA 1 c and creatinine level from laboratory findings. Estimated glomerular filtration rate (eGFR) was calculated. Results The average results of fasting plasma glucose test were 8.43 mmol/L, of HbA1c 7.15%, and of creatinine 79.00 µmol/L. In 19.12% of patients eGFR was <60 mL/min/1.73m 2. 80.15% were overweight and 38.97% had a body mass index (BMI) of 30 kg/ m 2 or higher. Morbid obesity was recorded in 2.94% of patients. Females had a statistically significantly higher hip circumference (p=0.002) and BMI (p=0.019), while males had a statistically significantly higher waist-to-hip ratio (p=0.006) and BMI (p=0.007). Conclusion The patients did not reach the target value of fasting plasma glucose (<7mmol/L) and HbA1c was above recommended (<7%). Given that the patients were elderly, glucoregulation can be considered as adequate. The average eGFR classified the patients into G2 group (mildly decreased glomerular filtration). The mean BMI was not within the recommended values. It is important to educate patients on a healthy diet and physical activity, to control their weight, but also to choose medications that reduce weight in addition to glycaemic control.
Background: Postmenopausal women experience an increased risk of cardiovascular diseases due to estrogen deficiency, which induces endothelial dysfunction. Statins primarily lower cardiovascular risk by altering lipid profiles, but they also exert non-lipid-modifying, pleiotropic effects on the vascular endothelium. This prospective observational study was aimed to evaluate and compare the impact of atorvastatin and rosuvastatin on plasma markers of endothelial dysfunction, endocan and endoglin, in postmenopausal women undergoing primary cardiovascular prevention. Methods: A total of 128 postmenopausal Croatian women (aged 45–70 years) with dyslipidemia were prospectively enrolled and assigned to two treatment groups receiving either atorvastatin or rosuvastatin therapy based on primary care clinical management. Cardiovascular risk was evaluated using the SCORE2 algorithm, and statin doses were titrated up to 16 weeks until target LDL-C values were achieved. Plasma concentrations of endocan and endoglin, alongside lipid profiles, were quantified via ELISA and laboratory analyses before and after the treatment period. Results: Atorvastatin and rosuvastatin therapies significantly decreased plasma concentrations of both endocan and endoglin (p < 0.001 for both groups). No statistically significant differences in the absolute changes in these biomarkers were observed between therapy groups. The reduction in endocan and endoglin levels occurred independently of whether the participants achieved their clinical target LDL-C values. While statin-induced reduction in endoglin was directly driven by the extent of LDL-C lowering, the decrease in endocan occurred independently of lipid changes, with both biomarker reductions being greatest in women with higher baseline levels regardless of statin type or dose. ROC curve analysis demonstrated that neither biomarker had significant clinical discriminatory ability to predict the attainment of target LDL-C levels. Conclusions: Atorvastatin and rosuvastatin treatment was associated with significant reductions in plasma endocan and endoglin concentrations in postmenopausal women receiving primary cardiovascular prevention.
27 April 2020 in Southeastern European medical journal
Aim: The study aimed to examine LDL cholesterol, triglyceride and urate levels in patients of both sexes with type 2 diabetes mellitus (DM2T) in family medicine offices and to examine whether there is a difference in these parameters between obese patients and patients with normal body weight with DM2T, and between patients with and without manifest cardiovascular diseases. Participants and methods: The study was organized as a cross-sectional study. It included 136 participants of both sexes diagnosed with DM2T, who were divided into groups of patients with or without adiposity and into groups of patients with or without experience of cardiovascular event. General and demographic data were collected, as well as data on experiencing cardiovascular events and levels of LDL cholesterol, triglycerides and urates. Results: The average LDL cholesterol level was 2.93 mmol/L, the average triglyceride level was 1.65 mmol/L and the average urate level was 326.36 µmol/L. Only 12.5% of participants reached target LDL cholesterol levels, while levels of triglycerides and urates were within recommended limits. 24.3% of participants had experienced cardiovascular events and 39.7% of participants were obese. There was no significant difference in levels of LDL cholesterol, triglycerides and urates in participants who had experienced a cardiovascular event and those who had not. There was a significantly higher concentration of triglycerides in obese patients than in patients with normal body weight (p = 0.005). Conclusion: In addition to regulation of glycaemia in patients with DM2T, statin doses should be increased in order to reach the target levels of LDL cholesterol. When it comes to obese patients, education courses on physical activity and diet should be conducted more often and, if necessary, fibrates should be included in therapy in order to reduce additional cardiovascular risks.
Objective: To examine patterns of inflammatory markers, kidney function, and clinical outcomes in patients with type 2 diabetes (T2D) hospitalized for COVID-19, with particular focus on the impact of therapy with hydroxymethylglutaryl-CoA reductase inhibitors (statins). Methods: We conducted a retrospective analysis of 440 T2D patients, divided into those who were on statin therapy prior to hospitalization and those who were not. Clinical characteristics, laboratory markers of inflammation, kidney function, and the requirement for invasive ventilation were compared between the groups. Results: Patients were predominantly older adults with a high burden of comorbidities, most commonly arterial hypertension and chronic kidney disease, and presented with elevated inflammatory markers and hyperglycemia at admission. Statin users more frequently had cardiovascular comorbidities and showed lower unadjusted interleukin-6 (IL-6) and ferritin levels, although these differences were not significant after multivariable adjustment. Importantly, statin therapy was independently associated with lower odds of mechanical ventilation in multivariable analysis. Conclusions: Despite a higher prevalence of cardiovascular comorbidities, diabetic patients receiving statins had lower odds of mechanical ventilation. No independent association with inflammatory markers was confirmed, and the observed relationship with respiratory outcomes should be interpreted cautiously given the observational design.